Home > Insider Trading > Filing (0001104659-20-099718)

Filing Details

Accession Number:: 0001104659-20-099718
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-08-27 20:14:16
Reporting Period:: 2020-08-25

Accepted Time:: 2020-08-27 20:14:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1693415	Translate Bio Inc.	TBIO	()	MA

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1030575	Francois Jean Formela	C/O Translate Bio, Inc. 29 Hartwell Avenue Lexington MA 02421		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-08-25	34,410	$15.00	3,887,600	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-08-26	44,381	$14.80	3,843,219	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-08-27	10,097	$14.38	3,833,122	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

Represents shares sold by Atlas Venture Fund VIII, L.P. ("Atlas VIII"). Atlas Venture Associates VIII, L.P. ("AVA VIII LP") is the general partner of Atlas VIII. Atlas Venture Associates VIII, Inc. ("AVA VIII INC") is the general partner of AVA VIII LP. Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by Atlas VIII, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 - $15.01, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 - $15.09, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.25 - $14.61, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4.
These shares are held directly by Atlas VIII. The sole general partner of Atlas VIII is AVA VIII LP. AVA VIII INC is the sole general partner of AVA VIII LP. Dr. Formela is a director of AVA VIII INC and disclaims Section 16 beneficial ownership of the securities held by Atlas VIII, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Dr. Formela is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.